PhotonPharma, a biopharmaceutical company focused on developing innovative cancer treatments, has successfully secured $2.5 million in seed funding. This investment will fuel the advancement of Innocell, a promising therapy designed to target advanced ovarian cancer.   The funding round marks a significant milestone for PhotonPharma as the company prepares to initiate a Phase I clinical trial for Innocell. The trial is expected to enroll its first patient in the fourth quarter of 2024, providi...